

PRESS RELEASE – FOR IMMEDIATE RELEASE

**IntegraGen Collaborating with PICCOLO Study Investigators to Validate Hsa-miR-31-3p  
Metastatic Colorectal Cancer Biomarker**

Evry, France (December 16, 2014) - IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, today announced a collaboration with investigators from the PICCOLO study to validate the oncology biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be a predictor of progression free survival (PFS) in patients with metastatic colorectal cancer (mCRC) treated with anti-EGFR therapy.

The PICCOLO study is a randomized clinical trial comparing irinotecan alone to irinotecan in combination with panitumumab, an anti-EGFR antibody, in 460 KRAS wild-type mCRC patients who progressed after receiving fluoropyrimidine treatment with or without oxaliplatin. Initial results from the PICCOLO study were published in *Lancet Oncology* in July 2013. While the study authors reported no difference in overall survival (OS) between the two study arms, individuals in the panitumumab group had significantly improved progression free survival (PFS) versus the control arm. The present collaboration with IntegraGen will explore the expression levels of hsa-miR-31-3p in primary tumors from patients enrolled in the PICCOLO study and aims to reconfirm the ability of this biomarker to predict patient outcomes.

“This collaboration will allow us to develop further evidence that the miR-31-3p biomarker predicts response to anti-EGFR therapy in wild-type KRAS patients with metastatic colorectal cancer from a large randomized prospective trial” stated Francois Liebaert, M.D., IntegraGen’s Vice-President of R&D and Medical Affairs. “We are enthused by the opportunity to work with the investigators from the PICCOLO study and the ability to obtain data on miR-31-3p expression levels from this large patient cohort.”

“This collaboration with IntegraGen will permit us to conduct further translational research which will help us to explain the results we observed in the PICCOLO Study” commented Dr. Matthew Seymour, Professor of Gastrointestinal Cancer Medicine at the University of Leeds and Chief Investigator for the PICCOLO Study. “Our objective with this research is to meet the need for selection biomarkers beyond the current reliance on KRAS and refine positive or negative selection biomarkers in prospective clinical trials analysis for making the best use of an effective targeted therapy for the benefit of the patients.”

The PICCOLO Study is funded by [Cancer Research UK](#) (clinical trial number ISRCTN93248876).

**ABOUT INTEGRAGEN**

IntegraGen is a company specialized in deciphering the human genome by performing genomic analyses for academic and private laboratories and developing diagnostic tools within the fields of oncology and autism. IntegraGen’s oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. For autism, IntegraGen has developed the ARISK® Test, the first test marketed in the United States to assess the risk of autism spectrum disorder in children.

As of June 30 2014, IntegraGen had 34 employees and had generated revenue of €5.4 million in 2013. Based in the Evry Genopole, Integragen also has an office in the Cambridge, Massachusetts in the United States.

IntegraGen is listed on Alternext of Euronext Paris (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

For more information on IntegraGen visit [www.integragen.com](http://www.integragen.com).

## **CONTACTS**

### **INTEGRAGEN**

Bernard COURTIEU  
President, Managing Director

Laurence RIOT LAMOTTE  
CFO  
[contact@integragen.com](mailto:contact@integragen.com)  
Tel.: +33 (0)1 60 91 09 00

### **NEWCAP.**

#### **Investor and Media relations**

Emmanuel HUYNH  
Louis-Victor DELOUVRIER  
[integragen@newcap.fr](mailto:integragen@newcap.fr)  
Tel.: +33 (0)1 44 71 94 94